Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 1540 • 2018 ACR/ARHP Annual Meeting
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Debbie Olsson-White¹, John Olynyk^2,3, Warren Raymond^4,5, Shereen Paramalingam^1,5 and Helen Keen^1,6, ¹Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, ²Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, Australia, ³School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁴Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia, ⁵University of Western Australia, Crawley, Australia, ⁶University of Western Australia, Perth, Australia
Background/Purpose: MTX is the cornerstone of treatment of RA. A relatively rare side effect is liver fibrosis and cirrhosis, the incidence in patients on long-term…
Abstract Number: 2036 • 2018 ACR/ARHP Annual Meeting
Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Ankita Singh¹, Ramnath Misra² and Amita Aggarwal², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Methotrexate (MTX) is first line of therapy to treat Rheumatoid Arthritis (RA) patients and one third of patients do not respond to this drug.…
Abstract Number: 2460 • 2018 ACR/ARHP Annual Meeting
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Yoshihiko Ikeno¹, Youkou Kobayashi², Ikuo Akutsu³, Hirokuni Hirata⁴, Masafumi Arima⁵ and Kazuhiro Kurasawa⁶, ¹Rheumatology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ²Hematology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ³Respiratory and allergy, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ⁴Respiratory and allergy, Dokkyo Medical University Saitama Medical center, Saitama, Japan, ⁵Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan, ⁶Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) was first reported in 1991. The symptom is known to spontaneously regress after suspending the use of MTX, suggesting its…
Abstract Number: 289 • 2018 ACR/ARHP Annual Meeting
Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
Nizar Abdulateef Al Ani¹, Faiq Isho Gorial¹, Eman Khedir², Ahmed Hussein², Yasser El Dershaby³ and Ali AlJabban⁴, ¹Baghdad Teaching Hospital, College of Medicine, Baghdad University, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad University, Baghdad, Iraq, ³Pfizer, Dubai, United Arab Emirates, ⁴Pfizer, Baghdad, Iraq
Background/Purpose: Real-world data on adherence to TNFα inhibitors in patients with RA are missing from many regions, including the Middle East. This study evaluated the…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting
Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate
Michael D. George¹, Brian Sauer², Chia-Chen Teng, MS², Grant Cannon², Bryant R. England³, Gail S. Kerr⁴, Ted R. Mikuls⁵ and Joshua Baker⁶, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴VAMC, Georgetown University, Washington, DC, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting
Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…
Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 517 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis
Jenny Wan¹, Michele Spence², Fang Niu², Rita Hui³, Stephen Cheng¹, Logan Saito⁴ and Antony Lin⁵, ¹Kaiser Permanente Drug Information Services - California Regions, Downey, CA, ²Kaiser Permanente Pharmacy Outcomes Research Group, Downey, CA, ³Kaiser Permanente Pharmacy Outcomes Research Group, Oakland, CA, ⁴Kaiser Permanente Southern California Clinical Pharmacy Services, Downey, CA, ⁵Rheumatology, Kaiser Permanente Fontana Medical Center, Fontana, CA
Background/Purpose: Systemic methotrexate (MTX) is the first-line disease-modifying antirheumatic drug (DMARD) for treating early and established rheumatoid arthritis (RA). When compared to oral MTX, subcutaneous…
Abstract Number: 518 • 2017 ACR/ARHP Annual Meeting
The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients
Antony Lin¹, Qiaowu Li², Jiaxiao Shi², Serena Lin³, Danielle Wang⁴, Jenny Wan⁵, Kevin Lee³, Hung-Fu Tseng² and TC Cheetham⁶, ¹Southern California Permanente Medical Group, Pasadena, CA, ²Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, ³Stanford University, Stanford, CA, ⁴UCI Medical Center, Irvine, CA, ⁵Kaiser Permanente Drug Information Services - California Regions, Downey, CA, ⁶Western University of Health Sciences, Pomona, CA
Background/Purpose: To investigate the efficacy and safety of zoster vaccines administered in rheumatoid arthritis(RA) patients taking methotrexate(MTX). Methods: By reviewing data through the…
Abstract Number: 534 • 2017 ACR/ARHP Annual Meeting
Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study
René Westhovens¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset² and Pille Harrison², ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 539 • 2017 ACR/ARHP Annual Meeting
Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis
Sahar Janjua¹, Andreea Bujor¹, Michael P. LaValley², Josefina Duran³, Jürgen Braun⁴ and David T. Felson⁵, ¹Department of Rheumatology, Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Pontificia Universidad Católica de Chile, Santiago, Chile, ⁴Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Methotrexate (MTX) is the mainstay first-line therapy for rheumatoid arthritis (RA), and it can be given orally or parenterally. Bioavailability of oral MTX may…
Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting
Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³ and Hélène Herman-Demars³, ¹Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France
Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…
Abstract Number: 1738 • 2017 ACR/ARHP Annual Meeting
The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz², Cristina Bohórquez Heras³, Maria Dolores Sosa Reina², Atusa Movasat³, Ana Pérez Gómez³, Lucía Ruiz Gutiérrez³, Ana Sánchez Atrio³, Eduardo Cuende Quintana³, Maria José León³, David Diaz², Fernando Albarrán Hernández³ and Melchor Alvarez-Mon^2,3, ¹Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares. Madrid, Spain, ²Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares, Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain
Background/Purpose: Mechanisms regulating the autoimmune response in rheumatoid arthritis (RA) are not well understood. However, it is known that T CD4+ lymphocytes play a pivotal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.